Can you describe a patient with AD who has more moderate but persistent disease, who is doing fairly well, with topical treatments, but in whom you felt intensification with a systemic type 2 cytokine-signaling inhibitor was appropriate?
Can you describe a patient with AD who has more moderate but persistent disease, who is doing fairly well, control-wise, with topical treatments, but in whom you felt intensification with a systemic type 2 cytokine-signaling inhibitor was appropriate?
Presenter
Chief of Pediatric and Adolescent Dermatology
Rady Children's Hospital-San Diego
Vice Chair, Department of Dermatology
Professor of Dermatology and Pediatrics
UC San Diego School of Medicine